Integrating multi-omics methods for personalized treatment of refractory chronic myelomonocytic leukemia with NRAS and TET2 mutations  

作　　者：Chuandong Hou Bo Yang Yue Wang Lili Cai Ran Qin Bo Guo Jie Geng XueChun Lu 

机构地区：[1]Department of Hematology,The Second Medical Center,Chinese PLA General Hospital,Beijing 100853,China [2]Medical School of Chinese PLA,Beijing 100853,China [3]National Institutes for Food and Drug Control,Beijing 102629,China [4]Department of Laboratory Medicine,The Second Medical Center,Chinese PLA General Hospital,Beijing 100853,China [5]School of Basic Medical Sciences,Shanxi Medical University,Taiyuan,Shanxi 030002,China

出　　处：《Cancer Pathogenesis and Therapy》2025年第2期173-175,共3页癌症发生与治疗(英文)

基　　金：supported by the Multi-Center Clinical Research Project of the National Clinical Research Center for Geriatric Diseases(No.NCRCG-PLAGH-20230010);the Key Military Health Project(No.23BJZ25).

摘　　要：Chronic myelomonocytic leukemia(CMML),a rare and malignant hematologic disorder,is classified as a myelodysplastic/myeloproliferative neoplasm(MDS/MPN).1 It poses a significant risk of progression to acute myeloid leukemia and is generally associated with a poor prognosis.2 CMML predominantly affects older adults,and treatment often involves demethylation therapy tailored to the patient's age and overall health.3 However,the complete remission rate for patients with CMML undergoing demethylation therapy is<20%and is frequently accompanied with severe side effects.1 Here,we discuss the case of an 84-year-old male diagnosed with CMML 6 years earlier,who experienced significant bone marrow suppression following demethylation therapy.By integrating multiomics data with bioinformatics,we developed and applied a novel approach of trimetinib monotherapy.This treatment resulted in notable improvements in hematopoietic function and overall quality of life,offering a promising strategy for managing CMML.

关 键 词：chronic myelomonocytic leukemia cmml personalized treatment demethylation therapy acute myeloid leukemia refractory chronic myelomonocytic leukemia multi omics Nras mutations Tet mutations 

分 类 号：R733.7[医药卫生—肿瘤]